Weijtens M E, Willemsen R A, Hart E H, Bolhuis R L
Department of Clinical and Tumor Immunology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Gene Ther. 1998 Sep;5(9):1195-203. doi: 10.1038/sj.gt.3300696.
Genetic engineering of T lymphocytes for adoptive clinical immunotherapy calls for efficient gene transduction methods. Therefore, a transient retroviral gene transduction system 'STITCH' was developed comprising pSTITCH retroviral vector encoding the transgene, plasmids encoding Moloney murine leukemia virus gag/pol and gibbon ape leukemia virus envelope, and the human kidney cell line 293T as a packaging line. Cotransfection of retroviral vector and packaging plasmids in 293T cells results in the production of GALV env pseudotyped viral particles with a titer of 10(7) infectious units per milliliter. The 'STITCH' gene transduction system efficiently transduces genes into activated human T lymphocytes derived from healthy donors and cancer patients. The efficacy of gene transduction is donor-independent. A direct application of the 'STITCH' gene transduction system is the genetic engineering of activated human T lymphocytes to induce expression of antibody based chimeric receptors in their membrane. Introduction of these chimeric receptors into activated human T lymphocytes graft these cells with specificity for, for example, renal cell carcinoma. In order to study the effect of the chimeric receptor gene structure on the processes ultimately leading to functional membrane expression, we designed a number of different chimeric receptor gene structures and subsequently compared their membrane expression on 293T cells and activated human T lymphocytes. Distinct membrane expression densities were observed on 293T cells and human T lymphocytes for the different chimeric receptor gene constructs. Gene transduction of activated human T lymphocytes with four out of five chimeric receptor gene constructs resulted in functional expression of chimeric receptor as demonstrated by specific recognition and cytolysis of renal cell carcinoma.
用于过继性临床免疫治疗的T淋巴细胞基因工程需要高效的基因转导方法。因此,开发了一种瞬时逆转录病毒基因转导系统“STITCH”,它由编码转基因的pSTITCH逆转录病毒载体、编码莫洛尼鼠白血病病毒gag/pol和长臂猿白血病病毒包膜的质粒以及作为包装细胞系的人肾细胞系293T组成。在293T细胞中共转染逆转录病毒载体和包装质粒可产生滴度为每毫升10(7)个感染单位的GALV env假型病毒颗粒。“STITCH”基因转导系统能有效地将基因转导到来自健康供体和癌症患者的活化人T淋巴细胞中。基因转导的效果不依赖于供体。“STITCH”基因转导系统的直接应用是对活化的人T淋巴细胞进行基因工程改造,以诱导其膜上基于抗体的嵌合受体的表达。将这些嵌合受体引入活化的人T淋巴细胞可使这些细胞具有例如对肾细胞癌的特异性。为了研究嵌合受体基因结构对最终导致功能性膜表达的过程的影响,我们设计了许多不同的嵌合受体基因结构,随后比较了它们在293T细胞和活化的人T淋巴细胞上的膜表达。对于不同的嵌合受体基因构建体,在293T细胞和人T淋巴细胞上观察到了不同的膜表达密度。用五种嵌合受体基因构建体中的四种对活化的人T淋巴细胞进行基因转导,结果显示嵌合受体具有功能性表达,这通过对肾细胞癌的特异性识别和细胞溶解得以证明。